Syra Health Corp. SYRA
0.88
0.02
2.33%
as of 25 Sep
- Market cap
- $1.1M
- P/E
- 90.0×
Follow SYRA
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.97 | 0.39 | 0.15 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(22.35) | (22.35) | (3.05) | (14.42) | (3.69) |
P/B ratio |
18.50 | 18.50 | 1.34 | 1.08 | 0.51 |
Price to Tangible BV |
18.50 | 18.50 | 1.34 | 1.08 | 0.51 |
EV/Sales |
0.00 | 0.00 | 0.70 | 0.31 | 0.17 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.83) | (4.83) | (1.39) | (0.84) | (2.70) |
EV/FCF |
(4.61) | (4.61) | (1.38) | (0.83) | (2.66) |
Quick Ratio |
0.80 | 0.78 | 4.83 | 5.01 | 3.75 |
Current Ratio |
0.84 | 0.92 | 5.25 | 5.47 | 4.06 |
Net Debt/EBITDA |
32.26 | (0.36) | 1.16 | 0.65 | 1.83 |
Debt/Assets |
0.00% | 32.36% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 1.06 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 3.93 | 1.52 | 1.86 | 2.24 |
Operating CF/Net income |
26.73 | 1.06 | 0.94 | 0.78 | 0.50 |
Capex/Depreciation |
(31.50) | (4.20) | (0.31) | (0.18) | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (602.62%) | (124.42%) | (109.09%) | (36.02%) | |
| 0.00% | (148.31%) | (81.14%) | (87.40%) | (27.78%) | |
ROIC |
0.00% | (89.62%) | (246.18%) | (486.97%) | (116.90%) |
Return on Tangible Assets |
5.15% | 29,833.80% | (74.39%) | (135.88%) | (43.28%) |
Average Days of Receivables |
67.46 | 78.04 | 73.54 | 31.13 | 46.39 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 4.35% | 7.33% | 0.94% |
Selling, General and Administrative Expense of Revenue |
24.01% | 37.39% | 62.09% | 52.17% | 35.51% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.05% | 0.59% | 0.75% | 1.36% |
Graham Net Nets |
0.11 | 0.11 | 0.72 | 0.82 | 1.93 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(17.50%) | (17.50%) | (54.89%) | (131.71%) | (83.67%) |
Free Cash Flow Yield |
(22.94%) | (22.94%) | (51.71%) | (95.06%) | (42.49%) |
Revenue per Share |
1.69 | 1.85 | 1.13 | 1.06 | 0.61 |
Operating CF per Share |
(0.11) | (0.74) | (0.57) | (0.39) | (0.04) |
Capex per Share |
(0.01) | (0.04) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.11) | (0.78) | (0.57) | (0.39) | (0.04) |
Cash per Share |
0.12 | 0.00 | 0.67 | 0.32 | 0.14 |
Shareholders Equity per Share |
(0.01) | 0.23 | 0.82 | 0.38 | 0.18 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.01) | 0.23 | 0.82 | 0.38 | 0.18 |
Free Cash Flow |
(0.09) | (2.37) | (2.77) | (2.94) | (0.45) |
Working Capital |
(0.07) | (0.12) | 3.87 | 2.74 | 2.06 |
Capital Expenditures |
(0.01) | (0.12) | (0.02) | (0.01) | 0.00 |
Net Current Asset Value |
(0.16) | (0.18) | 3.87 | 2.55 | 2.06 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(0.23%) | (37.71%) | (53.28%) | (47.10%) | (12.40%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.03 | 0.26 | 0.62 | 2.30 | 2.93 |
Cash ROIC |
(101.51%) | (160.97%) | (38.91%) | (56.11%) | (12.25%) |
Accounts Receivable Turnover |
0.00 | 7.69 | 4.77 | 8.91 | 9.04 |
Accounts Payable Turnover |
0.00 | 19.28 | 9.17 | 22.42 | 27.14 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
14.94 | 34.64 | 41.19 | 5.87 | 19.07 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.73 | 1.16 | 0.90 | 0.80 |
Average Payables |
— | 0.24 | 0.45 | 0.28 | 0.17 |
Average Assets |
— | 1.43 | 3.62 | 4.30 | 3.23 |
Average Common Equity |
— | 0.35 | 2.36 | 3.45 | 2.49 |
Columns are period end dates